Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2002 2
2003 7
2004 5
2005 3
2006 3
2007 8
2008 12
2009 11
2010 10
2011 9
2012 16
2013 14
2014 18
2015 18
2016 18
2017 28
2018 29
2019 18
2020 16
2021 13
2022 15
2023 36
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

266 results

Results by year

Filters applied: . Clear all
Page 1
Development of a Safety Surveillance Plan for the Academic Medicine Sponsor Performing First-in-Human Cellular Therapy Clinical Trials: A Report from the Consortium for Pediatric Cellular Immunotherapy.
Adams C, Keller M, Michlitsch JG, Aguayo-Hiraldo P, Chen K, Hossain MZ, Davis A, Park JR, Verneris MR, Gardner RA. Adams C, et al. Among authors: park jr. Transplant Cell Ther. 2024 May;30(5):475-487. doi: 10.1016/j.jtct.2024.02.022. Epub 2024 Mar 4. Transplant Cell Ther. 2024. PMID: 38447751 Review.
Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial.
Hogarty MD, Ziegler DS, Franson A, Chi YY, Tsao-Wei D, Liu K, Vemu R, Gerner EW, Bruckheimer E, Shamirian A, Hasenauer B, Balis FM, Groshen S, Norris MD, Haber M, Park JR, Matthay KK, Marachelian A. Hogarty MD, et al. Among authors: park jr. Br J Cancer. 2024 Mar;130(5):788-797. doi: 10.1038/s41416-023-02525-2. Epub 2024 Jan 10. Br J Cancer. 2024. PMID: 38200233 Free PMC article. Clinical Trial.
Factors influencing parents' choice of palliative treatment goals for children with relapsed or refractory neuroblastoma: A multi-site longitudinal survey study.
Kaye EC, Smith J, Zhou Y, Bagatell R, Baker JN, Cohn SL, Diller LR, Glade Bender JL, Granger MM, Marachelian A, Park JR, Rosenberg AR, Shusterman S, Twist CJ, Mack JW. Kaye EC, et al. Among authors: park jr. Cancer. 2024 Apr 1;130(7):1101-1111. doi: 10.1002/cncr.35149. Epub 2023 Dec 15. Cancer. 2024. PMID: 38100619
Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to 131 I-MIBG in patients with relapsed/refractory neuroblastoma.
Batra V, Gikandi A, Pawel B, Martinez D, Granger MM, Marachelian A, Park JR, Maris JM, Vo KT, Matthay KK, DuBois SG. Batra V, et al. Among authors: park jr. Pediatr Blood Cancer. 2024 Jan;71(1):e30743. doi: 10.1002/pbc.30743. Epub 2023 Oct 26. Pediatr Blood Cancer. 2024. PMID: 37885116
Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma.
Hess G, Dreyling M, Oberic L, Gine E, Zinzani PL, Linton K, Vilmar A, Jerkeman M, Chen JMH, Ohler A, Stilgenbauer S, Thieblemont C, Lambert J, Zilioli VR, Sancho JM, Jimenez-Ubieto A, Fischer L, Eyre TA, Keeping S, Park JE, Wu JJ, Nunes A, Reitan J, Wade SW, Salles G. Hess G, et al. Among authors: park je. Leuk Lymphoma. 2024 Jan;65(1):14-25. doi: 10.1080/10428194.2023.2268228. Epub 2024 Jan 10. Leuk Lymphoma. 2024. PMID: 37840282
266 results